Income Statement
IMMUNEERING CORP
IMRX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | 0.00 | 0.32 | 2.08 |
|
Cost of Revenue
|
- | - | 0.00 | 0.16 | 1.15 |
|
Gross Profit
|
- | - | 0.00 | 0.16 | 0.93 |
|
Operating Expenses
|
59.38 | 64.07 | 58.41 | 51.90 | 34.81 |
|
Research & Development
|
42.05 | 47.96 | 41.62 | 36.27 | 26.54 |
|
Selling, General & Administrative
|
17.30 | 16.08 | 16.76 | 15.61 | 8.27 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-59.38 | -64.07 | -58.41 | -51.74 | -33.89 |
|
Non-Operating Income
|
- | - | - | -1.23 | -0.04 |
|
Interest Income
|
3.04 | 2.59 | 3.61 | 1.01 | 0.17 |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
0.31 | 0.44 | 1.33 | 0.22 | -0.13 |
|
Income Before Tax
|
- | - | - | -50.51 | -33.84 |
|
Income Tax Expense
|
- | - | - | 0.00 | -0.31 |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-56.02 | -61.04 | -53.47 | -50.51 | -33.54 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-59.05 | -64.07 | -58.41 | -51.74 | -33.89 |
|
Earnings Per Share (Basic)
|
-1.27 | -2.04 | -1.88 | -1.91 | -2.46 |
|
Diluted EPS
|
-1.27 | -2.04 | -1.88 | -1.90 | -2.46 |
|
Weighted Average Shares
|
44.01 | 29.98 | 28.42 | 26.39 | 13.61 |
|
Diluted Weighted Avg Shares
|
44.01 | 29.98 | 28.42 | 26.39 | 13.61 |
|
Comprehensive Income
|
-55.94 | -61.04 | -53.44 | -50.49 | -33.58 |